Shareholders meeting

September 8, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub.: Proceedings of the 15th Annual General Meeting (AGM) of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) (‘the Company’) held on September 8, 2026 The 15th AGM of the Company was held on Tuesday, September 8, 2026 at 3.00 p.m. through Video Conferencing (VC)/Other Audio Visual Means (OAVM) and the webcast facility was provided to the Members. In this regards, please find enclosed the following: 1. Summary of the proceedings of the AGM of the Company as required under Regulation 30 read with Para A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (‘Listing Regulations’) - Annexure I. 2. Report of the Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 of today’s date - Annexure II. The Scrutinizer’s Report is made available on the Company’s website at www.alivus.com. 3. Voting results of the business transacted at the AGM, as required under Regulation 44(3) of the Listing Regulations - Annexure III. This is for your Information and records. Thanking You, Yours Faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: as above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing, 4th Floor, Mahaka li Plot No 170-172, Chandramouli Industrial Estate Caves Road, Andheri East, Mumba–i 400093 , India Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Annexure I Summary of Proceedings of the 15th Annual General Meeting The 15th Annual General Meeting (‘AGM’) of the members of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) (‘the Company’) was held on Tuesday, September 8, 2026 at 3:00 p.m. (IST) via Video Conferencing (‘VC’)/ Other Audio Visual Means (‘OAVM’). In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the webcast facility was provided to the shareholders. The said AGM commenced at 3.00 p.m. and concluded at 4.40 p.m. Mr. Hiren Patel, Chairman & Non-Executive Director presided over the meeting and welcomed the Members and Directors participating through video conference. He introduced the Directors, the Chief Financial Officer and the Company Secretary & Compliance Officer. All the Directors of the Company attended the AGM. The Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders’ Relationship Committee were present at the AGM to address the queries of the Members, if any. The representatives of Statutory, Secretarial, Internal and Cost Auditors were also present at the AGM through Number of Shareholders present in the Meeting through VC/OAVM - 38 The requisite quorum being present, the Chairman called the Meeting to order. The Company Secretary informed the Members that the Registers as required under the Companies Act, 2013 and other relevant documents mentioned in the Notice were available for inspection on the Company’s website. He further informed that the Notice of the AGM along with Integrated Annual Report for FY 2025-26 was sent through electronic mode to all the Members whose e-mail IDs were registered with the Depositories. Further, the Company had dispatched letters providing the web-link where complete details of the Annual Report is available, to those Members who have not registered their e-mail IDs. In compliance with the Circulars issued by the MCA and SEBI, the requirement of appointing proxies was not applicable. With the consent of the Members, the Notice of the AGM, Director’s Report & Financial Statements were taken as read. The Members were informed that the Statutory Auditors' Report and Secretarial Audit Report did not have any qualifications. The Chairman then addressed the Members inter-alia, highlighting Alivus Life Sciences' strong financial performance. He also outlined the Company's confidence in future growth through innovation, disciplined capital allocation, sustainability initiatives and continued value creation for shareholders. Dr. Yasir Rawjee, Managing Director & CEO addressed the Members on important milestones, FY26 performance, highlighting revenue growth, record profitability, business diversification, strong cash generation, sustainability initiatives and continued investments in manufacturing, R&D and technology. He also outlined the Company's future growth strategy through the "API+" approach, expansion into advanced pharmaceutical capabilities and a commitment to creating long-term value for shareholders and stakeholders. Further, the Company Secretary briefed the Members that the Company had provided its Members the facility to cast their vote electronically through the National Securities Depository Limited (‘NSDL’) system before the Meeting. He also informed that the e-voting facility was also made available at the AGM for the benefit of Members who were present during the Meeting and had not cast their votes earlier through remote e-voting. The Company Secretary further informed about the appointment of Mr. Bhadresh Shah, Practicing Company Secretary as the Scrutinizer to conduct the e-voting process in a fair and transparent manner pursuant to the provisions of Section 109 of the Companies Act, 2013 and the combined results of the remote e-voting before as well as e-voting during the AGM would be announced at earliest but within the statutory time permitted under the law. The results along with the Scrutinizer's Report would be intimated to the Stock Exchanges in terms of the Listing Regulations and would be placed on the website of the Company. The following resolutions set out in the Notice convening the AGM were put to vote by e-voting at the Meeting: Res. No. Agenda Item Type of Resolution Ordinary Business 1 To receive, consider, approve and adopt the Audited Financial Statements for the Ordinary financial year ended 31 March 2026 together with the reports of the Board and Auditors thereon. 2 To declare the final dividend of Rs. 5/- per equity share for the financial year ended Ordinary 31 March 2026. 3 To appoint a Director in place of Mr. Hiren Patel (DIN: 00145149) who retires by Ordinary rotation and being eligible, offers himself for re-appointment as per Section 152(6) of the Companies Act, 2013. Special Business 4 To ratify remuneration of the Cost Auditor of the Company for the financial year Ordinary ending 31 March 2027. The Company Secretary then invited the Members who had registered themselves as speakers to ask questions, seek clarifications or express their views on the performance of the Company and resolutions set out in the Notice. After giving sufficient time to all the speaker Members, the Managing Director & CEO appropriately responded to the queries raised by them. The Chairman, Mr. Hiren Patel, then delivered his closing remarks expressing gratitude to the Members for their continued support, participation in the AGM and sharing their thoughts on the performance of the Company. Lastly, he informed the Members that the e-voting facility would be kept open for 30 minutes to enable the Members to cast their vote who have still not cast their votes. The combined results of the remote e-voting before as well as e-voting during the AGM would be announced, intimated to the Stock Exchanges and would be placed on the website of the Company at earliest but within the statutory time permitted under the law. Upon co [Showing first 8,000 characters — download PDF for full document]